Hemophilia is a complex condition, and statistics show that India stands first place with the highest number of cases. Back in the day, life expectancy was only thirteen years. But with medical advancements now, there are Hemophilia treatments and medications available to manage the condition,
This is a unique, bispecific monoclonal antibody that connects active factor IX and factor X to restore hemostasis by replacing the role of lacking activated factor VIII.
Emicizumab is the first and only weekly subcutaneous prophylactic injectable that has been proven to prevent or lessen bleeding episodes while improving quality of life.
Emicizumab’s introduction is a big step forward in the treatment of Haemophilia A in India. This ground-breaking drug represents a fundamentally new approach to treating Haemophilia A and sets a new standard of care.